RETINOID, INTERFERON AND TAXOL EFFECTS IN BREAST CANCER

点击翻译按钮获取中文摘要

DESCRIPTION (Applicant's Description) Advanced breast cancer is only temporarily controlled with chemotherapy, which may be secondary to the development of tumor resistance mechanisms, such as bcl-2 overexpression. We used a pre-clinical epithelial cell line model to dissect out bcl-2 mechanisms of resistance derived from primary baby rat kidney epithelial cells (BRK), which were transfected with genes encoding the murine temperature sensitive p53(va1135) and a bcl-2 expression vector. We found that cells with p53 mutation and overexpression of bcl-2 were resistant to paclitaxel (TAX). In an attempt to sensitize these cells to TAX, we found several active agents capable of overcoming p53 and bcl-2 mediated resistance when combined with TAX including 13-cis retinoic acid and alpha interferon (CRA/IFN). We found that CRA/IFN also enhanced the effect of TAX on breast tumor cells (MCF-7) and prostate tumor cells (PC-3), both of which overexpress bcl-2. Additionally, we found that the effect of CRA/IFN on these cell lines correlated to reduction in expression of bcl-2. Based on these data, we hypothesized that agents that modulate the expression of bcl-2 and sensitize tumor cells to chemotherapy in the laboratory will translate into improved clinical results. To test this hypothesis, we completed a phase I clinical trial using CRA/IFN and TAX in patients with advanced malignancy and plan to treat patients with advanced breast cancer in a phase II trial with CRA/IFN in combination with TAX (using the dose established in our phase I trial) along with and a detailed analysis of bcl-2 in clinical specimens.